Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Authors :: G. A. Dashyan
V. F. Semiglazov
P. V. Krivorot’ko
T. Yu. Semiglazova
E. E. Topuzov
R. M. Paltuev
K. Yu. Zernov
V. S. Apollonova
S. S. Ereshchenko
A. V. Petrova
E. K. Zhil’tsova
O. A. Ivanova
Source :: Opuholi Ženskoj Reproduktivnoj Sistemy, Vol 12, Iss 1, Pp 46-51 (2016)
Publication Year :: 2016
Publisher :: ABV-press, 2016.
Abstract: Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.

Tools